Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Plenary Session (LBA's) & Presscast Presentations

Plenary Session & Late Breaking Abstracts (LBA1-5 & LBA4001)

 
Andrew Tutt, Judy Ellen Garber, Bella Kaufman, et al.
The study authors conclude that adjuvant olaparib following (neo)adjuvant chemotherapy significantly improved invasive disease-free survival and distant disease-free survival with acceptable toxicity in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Clinical trial information: NCT02032823
 
----------------------------------------------------------------------------------------------------------------------------------------------------------
 
Rui-hua Xu, Hai-Qiang Mai, Qiu-Yan Chen, et al.
The study authors conclude that adding the humanized IgG4K monoclonal antibody toripalimab specific for PD-1 to gemcitabine and cisplatin chemotherapy as 1st-line treatment for patients with advanced nasopharyngeal carcinoma provided superior progression-free survival and objective response rate as well as longer duration of response than gemcitabine and cisplatin alone with a manageable safety profile. The authors recommend the use of toripalimab with gemcitabine and cisplatin chemotherapy as the new standard of care for advanced nasopharyngeal carcinom. Clinical trial information: NCT03581786

SEE ALSO The ASCO Post

----------------------------------------------------------------------------------------------------------------------------------------------------------

Abstract: Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Linda R. Mileshkin, Kathleen N. Moore, Elizabeth Barnes, et al.
The study authors conclude that adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve overall and progression-free survival. Clinical trial information: ACTRN12610000732088.

SEE ALSO The ASCO Post

----------------------------------------------------------------------------------------------------------------------------------------------------------

Abstract: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J. Morris, Johann S. De Bono, Kim N. Chi, et al.
The study authors conclude that 177Lu-PSMA-617 plus standard of care is a well-tolerated regimen that improves radiographic progression-free survival. It also prolongs overall survival compared with standard of care alone in men with advanced-stage PSMA-positive mCRPC. This supports its adoption as a standard of care. Clinical trial information: NCT03511664

SEE ALSO The ASCO Post

----------------------------------------------------------------------------------------------------------------------------------------------------------

Abstract: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al.
The study authors conclude that Pembrolizumab showed a statistically significant and clinically meaningful improvement in disease-free survival versus placebo in patients with intermediate-high, high risk, or M1 NED renal cell carcinoma (M1 NED stands for no evidence of disease after primary tumor + soft tissue metastases completely resected ≤1 year from nephrectomy)). This is the first positive phase III study with a checkpoint inhibitor in adjuvant RCC. According to the study authors, these results support pembrolizumab as a potential new standard of care for patients with RCC in the adjuvant setting. Clinical trial information: NCT03142334

SEE ALSO The ASCO Post

----------------------------------------------------------------------------------------------------------------------------------------------------------

 
Ian Chau, Yuichiro Doki, Jaffer A. Ajani, et al.
The study authors conclude, that nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival versus chemotherapy, This goes along with durable objective responses and acceptable safety, in patients with advanced ESCC. Nivolumab plus chemotherapy and nivolumab plus ipilimumab both represent a potential new 1st-line treatment option. Clinical trial information: NCT03143153